LYMPHOGENiX aim to be a global leader in lymphatic science, addressing unmet needs in both human and animal health.
LYMPHOGENiX has raised $340K in total funding. The most recent round was Pre-Seed. The last funding was announced in July 2025.
LYMPHOGENiX's investors include Keio Innovation Initiative, Glocalink, S-Quatre Corporation, AndJ Holdings.
LYMPHOGENiX is headquartered in Covent Garden, United Kingdom.
LYMPHOGENiX aim to be a global leader in lymphatic science, addressing unmet needs in both human and animal health.
LYMPHOGENiX is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LYMPHOGENiX — Funding & Investors." VCBacked, July 8, 2025, https://www.vcbacked.co/company/lymphogenix. Accessed August 14, 2026.
VCBacked. (2025). LYMPHOGENiX — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/lymphogenix
{{cite web |title=LYMPHOGENiX — Funding & Investors |url=https://www.vcbacked.co/company/lymphogenix |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated